Court order extends Teva's asthma treatment exclusivity

Teva benefitted from a US court issuing a temporary restraining order to prevent Actavis Inc. from marketing its generic version of Pulmicort.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has benefitted from a New Jersey court ruling. In the ruling the court agreed to the request of AstraZeneca plc (NYSE; LSE: AZN) to issue a temporary restraining order to prevent Actavis Inc. (NYSE: ACT) from marketing its generic version of asthma treatment Pulmicort until April 12.

The ruling follows Monday's launch of Actavis's generic version of Pulmicort after the court found that it did not infringe the drug's patent.

Under a 2008 agreement with AstraZeneca, Teva has exclusive rights to sell a generic version of Pulimcort. Teva paid AstraZeneca $260 million in 2012 in royalties.

Published by Globes [online], Israel business news - - on April 3, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017